ASH 2018 | Venetoclax for treating CLL outside the clinical trial setting
VJHemOnc is committed to improving our service to you
Thanks for your feedback, this will help us improve our content for you!
Venetoclax, a BCL2 inhibitor, is approved for the treatment of relapsed/refractory chronic lymphocytic leukemia (CLL). Here, Lindsey Roeker, MD, of the Memorial Sloan Kettering Cancer Center, New York City, NY, discusses a study aiming to understand rates of select adverse events including cytopenia, infections, and clinical tumor lysis syndrome (TLS) in CLL patients treated with venetoclax in both community and academic settings. Speaking at the American Society of Hematology (ASH) 2018 Annual Meeting and Exposition in San Diego, CA, Dr Roeker discusses the tolerability, with adverse effects rates like those reported in clinical trials, and states that the dose reduction and interruptions did not appear to impact PFS.
Get great new content delivered to your inboxSign up